Targeted survival improvements in clinical trials: are you an absolutist or relativist?

Paul, J. (2014) Targeted survival improvements in clinical trials: are you an absolutist or relativist? Cancer, 121(3), pp. 335-338. (doi:10.1002/cncr.29031) (PMID:25278175) (PMCID:4328455)

[img]
Preview
Text
104154.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

136kB

Abstract

n this issue of Cancer, Castonguay et al highlight problems with reliably estimating the median OS in the control arm of clinical trials in ovarian cancer. This suggests that more careful reflection is generally required concerning how clinically relevant differences are determined and highlights further issues with the selection of overall survival as a primary endpoint. The article also raises questions regarding the prevalent standard statistical approach used to design and analyze studies with time to event outcomes.

Item Type:Articles (Editorial)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Paul, Mr James
Authors: Paul, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Cancer
Publisher:Wiley
ISSN:0008-543X
ISSN (Online):1097-0142
Copyright Holders:Copyright © 2014 The Author
First Published:First published in Cancer 121(3):335-338
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
615371Cancer Research UK Clinical Trials Unit - Core Programme FundingRobert JonesCancer Research UK (CAN-RES-UK)C1348/A15960RI CANCER SCIENCES
615372Cancer Research UK Clinical Trials Unit - Core Programme FundingRobert JonesCancer Research UK (CAN-RES-UK)C1348/A15960RI CANCER SCIENCES
615373Cancer Research UK Clinical Trials Unit - Core Programme FundingRobert JonesCancer Research UK (CAN-RES-UK)C1348/A15960RI CANCER SCIENCES